QPS Neuropharmacology Animal Models for Central Nervous System Diseases
The QPS preclinical Neuropharmacology group covers various validated transgenic and non-transgenic in vivo and in vitro models for neurodegeneration such as Alzheimer’s Disease, Parkinson’s Disease, for rare diseases including Huntington’s Disease and ALS, for lipid storage disease and dyslipidemia, and for diseases like psychosis, anxiety, schizophrenia, or autism.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The QPS preclinical Neuropharmacology group covers various validated transgenic and non-transgenic in vivo and in vitro models for neurodegeneration such as Alzheimer’s Disease, Parkinson’s Disease, for rare diseases including Huntington’s Disease and ALS, for lipid storage disease and dyslipidemia, and for diseases like psychosis, anxiety, schizophrenia, or autism.
Besides in vivo research we also offer biochemical and histological analyses. To support our clients in the best possible way, we use or adapt existing models, or establish new models specific to your research focus. While many of our models are solely available at QPS Neuropharmacology, all of them are well-characterized in house and published in peer reviewed high impact journals. The animal facility of QPS Neuropharmacology is AAALAC accredited. This quality seal combined with over 20 years of experience and a vast amount of historic data are a clear asset for our clients, who range from international biotech and pharma companies to academia and other non- profit organizations. We assist with designing a developmental plan for your small molecules or biologics and together with our DMPK and Toxicology colleagues we help you develop custom-built research solutions.
Our facilities include:
- Animal Facility
- In Vivo Research Laboratory
- Cell Culture Laboratory
- Biochemistry Laboratory
- Histology Laboratory
A flexible approach to neuropharmacology
In this application note, QPS describes how it offers you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models to guarantee that your new chemical or biological compounds are profiled in depth.
CNS drug development
In this white paper, QPS describes how it provides essential preclinical and clinical research services to help pharmaceutical and biotechnology companies around the globe accelerate the discovery and development of drugs to prevent, treat, and cure brain diseases, with a special focus on age-related neurodegenerative disorders such as Alzheimer’s and Parkinson’s Disease.
Three lessons to help accelerate pharmaceutical breakthroughs for CNS disorders
In this white paper, QPS details three important lessons to guide forward-thinking companies working to accelerate pharmaceutical breakthroughs.
